文献速递肿瘤 PET/CT

放射性标记胆碱PET及PET/CT在前列腺癌中的应用:20年临床研究的批判性再评价

PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-04-14

本文对放射性标记胆碱PET/CT在前列腺癌中的临床应用文献进行综合批判性综述,涵盖初始分期、生化失败、预后信息、治疗反应监测及指南推荐指征,并讨论方法学因素对研究结果的影响。

要点

  • 综述总结放射性标记胆碱PET/CT在前列腺癌初始分期及生化失败患者中的应用证据。
  • 综述探讨该技术提供前列腺癌特异性生存预后信息及监测治疗反应的能力。
  • 综述讨论方法学因素对研究结果或解读的潜在影响,并简述PET/MR及新示踪剂。

研究设计与样本

  • 本文为对放射性标记胆碱PET/CT在前列腺癌中临床应用文献的综合批判性综述,按发表年份及与泌尿外科、放疗和肿瘤学应用的关系将临床研究任意分为三个时期。

主要发现

  • 综述涵盖初始分期研究及更广泛的生化失败患者研究,并涉及预测PET/CT阳性的因素。
  • 综述审视放射性标记胆碱PET/CT提供前列腺癌特异性生存预后信息的能力。
  • 综述最后部分涉及放射性标记胆碱用于监测雄激素剥夺治疗、放疗和化疗反应。
  • 综述根据活检或组织学等标准验证过程所得信息讨论该技术的准确性和局限性。
  • 综述基于该技术引起的患者管理改变和治疗反应评估改变讨论其临床影响。

临床怎么用

  • 综述阐述指南官方认可的PET/CT当前适应证及临床实践中常规执行的指征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We here aim to provide a comprehensive and critical review of the literature concerning the clinical applications of positron emission tomography/computed tomography (PET/CT) with radiolabeled choline in patients with prostate cancer (PCa). We will initially briefly summarize the historical context that brought to the synthesis of [11C]choline, which occurred exactly 20 years ago. We have arbitrarily grouped the clinical studies in three different periods, according to the year in which they were published and according to their relation with their applications in urology, radiotherapy and oncology. Studies at initial staging and, more extensively, studies in patients with biochemical failure, as well as factors predicting positive PET/CT will be reviewed. The capability of PET/CT with radiolabeled choline to provide prognostic information on PCa-specific survival will also be examined. The last sections will be devoted to the use of radiolabeled choline for monitoring the response to androgen deprivation therapy, radiotherapy, and chemotherapy. The accuracy and the limits of the technique will be discussed according to the information available from standard validation processes, including biopsy or histology. The clinical impact of the technique will be discussed on the basis of changes induced in the management of patients and in the evaluation of the response to therapy. Current indications to PET/CT, as officially endorsed by guidelines, or as routinely performed in the clinical practice will be illustrated. Emphasis will be made on methodological factors that might have influenced the results of the studies or their interpretation. Finally, we will briefly highlight the potential role of positron emission tomography/magnetic resonance and of new radiotracers for PCa imaging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Giovacchini G, Giovannini E, Leoncini R, et al. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies. Eur J Nucl Med Mol Imaging. 2017. PMID: 28409220. doi:10.1007/s00259-017-3700-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。